• AAPL 194.685
  • TSLA 243.53
  • AMZN 146.43
  • BTC-USD 43915.6914
  • ETH-USD 2353.4312
  • EURUSD 1.0767
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. LEXX.US

Lexaria Bioscience Corp (LEXX NASDAQ) stock market data APIs

$1.49 0.05(3.5%) as of December 7, 2023

Lexaria Bioscience Corp Financial Data Overview

1.44
1.49
-
1.58
1.39
0.6488-3.5953
14 798 K
10 277 K
226 K
-0.12
0
0.897
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'LEXX',
Type: 'Common Stock',
Name: 'Lexaria Bioscience Corp',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000JQHT18',
ISIN: NULL,
CUSIP: NULL,
CIK: '1348362',
EmployerIdNumber: NULL,
FiscalYearEnd: 'August',
IPODate: '2006-10-10',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
GicSector: 'Health Care',
GicGroup: 'Pharmaceuticals, Biotechnology & Life Sciences',
GicIndustry: 'Biotechnology',
GicSubIndustry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Lexaria Bioscience Corp Fundamental Data is available in our Financial Data APIs

  • Net Revenue 226 K
  • EBITDA -6 388 625
  • Earnings Per Share -1.01
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Lexaria Bioscience Corp Earnings via APIs

  • Latest Release 2023-11-20
  • EPS/Forecast -0.13

Get Lexaria Bioscience Corp End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Lexaria Bioscience Corp latest news via APIs

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Eve...
  • APIS
  • CANNABINOIDS
  • COMPANY ANNOUNCEMENT
  • DEHYDRATECH
  • GLP-1 DRUGS
  • HEALTH
  • LEXARIA BIOSCIENCE CORP
  • NASDAQ: LEXX
  • NASDAQ:LEXX
  • NETWORKNEWSAUDIO
  • OTHER NEWS
  • PRESS RELEASES
  • TYPE 2 DIABETES

Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60...
  • GLP-1 DRUGS
  • LEXARIA BIOSCIENCE CORP
  • NASDAQ: LEXX
  • NASDAQ:LEXX
  • NETWORKNEWSWIRE
  • NEW ENGLAND JOURNAL
  • OF MEDICINE
  • PRESS RELEASES
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com